Clinical trialObservationalUnknown
Biomarker Study in Pancreatic Neuroendocrine Tumours
Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours
- Outcome
- Outcome unknown
- Phase
- Observational
- Status
- Unknown
- Study type
- Observational
- Start
- 1 May 2017
- Listed end
- 1 January 2022
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Correlation between FDG-PET and tumor biology
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 25 August 2017
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.